Patents Examined by Paul Dickinson
-
Patent number: 9741945Abstract: The present disclosure is directed to new photoluminescent metal-organic frameworks (MOFs). The newly developed MOFs include either non rare earth element (REE) transition metal atoms or limited concentrations of REE atoms, including: Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Y, Ru, Ag, Cd, Sn, Sb, Ir, Pb, Bi, that are located in the MOF framework in site isolated locations, and have emission colors ranging from white to red, depending on the metal concentration levels and/or choice of ligand.Type: GrantFiled: June 30, 2014Date of Patent: August 22, 2017Assignee: National Technology & Engineering Solutions of Sandia, LLCInventors: Tina M. Nenoff, Dorina Florentina Sava Gallis, Lauren E.S. Rohwer
-
Patent number: 9737614Abstract: Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.Type: GrantFiled: March 14, 2016Date of Patent: August 22, 2017Assignee: Memorial Sloan Kettering Cancer CenterInventors: Daniel A. Heller, Yosef Shamay
-
Patent number: 9724433Abstract: A dye loaded zeolite composite material comprises a plurality of zeolite crystals each having a plurality of straight through uniform channels extending between the proximal face and the distal face and having a channel axis parallel to and a channel width transverse to a longitudinal crystal axis A. Each channel contains a substantially linear arrangement of dye molecules comprising first and second dye molecules having an elongated shape with a longitudinal extension exceeding said channel width and a lateral extension not exceeding said channel width.Type: GrantFiled: December 10, 2012Date of Patent: August 8, 2017Assignees: Unversität ZürichInventors: Gion Calzaferri, Andreas Kunzmann, Dominik Bruehwiler
-
Patent number: 9717797Abstract: Nanoparticles comprise a drug, a first block polymer and a second block polymer. The first block polymer has a poly(ethylene oxide) (PEO) block and a polycarbonate block bearing a side chain aromatic nitrogen-containing heterocycle (N-heterocycle). The N-heterocycle can be in the form of a base, a hydrosalt of the base, a sulfobetaine adduct of the base, or a combination thereof. The second block polymer has a PEO block and a polycarbonate block bearing a side chain catechol group, which can be present as a catechol, oxidized form of a catechol, and/or a polymerized form of a catechol. The nanoparticles can be dispersed in water and are capable of controlled release of the drug.Type: GrantFiled: December 5, 2013Date of Patent: August 1, 2017Assignees: International Business Machines Corporation, Agency For Science, Technology And Research, Universidad del París Vasco/Euskal Herriko UnibertsitateaInventors: Julian M. W. Chan, Amanda C. Engler, James L. Hedrick, Xiyu Ke, Victor W. L. Ng, Haritz Sardon, Jeremy P. K. Tan, Yi Yan Yang
-
Patent number: 9717695Abstract: The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.Type: GrantFiled: May 18, 2013Date of Patent: August 1, 2017Assignee: Georgia State University Research Foundation, Inc.Inventors: Didier Merlin, Bo Xiao, Hamed Laroui
-
Patent number: 9694368Abstract: The present invention relates to a magnetic reagent, a magnetic reagent kit, a method for treating magnetic carriers, and a treatment device therefor, with an object of quickly and efficiently treating magnetic carriers of a micro particle diameter including nanosized magnetic carriers. The magnetic reagent or magnetic reagent kit includes: a plurality of magnetic carriers which can be magnetized by being exposed to a magnetic field, can be bonded to a predetermined chemical substance or living organism in a liquid, and that have a particle diameter that enables them to be suspended in the liquid; and a plurality of treatment promoting magnetic particles which can be magnetized by being exposed to a magnetic field and thus can have the magnetic carriers adsorbed on the surface thereof, are formed so that they can be moved within the liquid by movement of the liquid or by a magnetic field, and promote a treatment for capturing or re-suspension of the magnetic carriers.Type: GrantFiled: November 12, 2010Date of Patent: July 4, 2017Assignee: UNIVERSAL BIO RESEARCH CO., LTD.Inventor: Hideji Tajima
-
Patent number: 9694103Abstract: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.Type: GrantFiled: September 7, 2012Date of Patent: July 4, 2017Assignee: The Children's Hospital of PhiladelphiaInventors: Ivan Alferiev, Ilia Fishbein, Michael Chorny, Robert J. Levy, Benjamin Yellen, Darryl Williams
-
Patent number: 9676801Abstract: The present invention relates to the use of silver(I) monophosphine complexes as Active Pharmaceutical Ingredients (API's), including anticancer agents, for the treatment, diagnosis and/or prevention of cancer. The present invention also relates to pharmaceutical compositions containing such complexes and further extends to a method of treating or diagnosing a subject/patient suffering from cancer.Type: GrantFiled: December 6, 2012Date of Patent: June 13, 2017Assignee: UNIVERSITY OF JOHANNESBURGInventors: Reinout Meijboom, Marianne Jacqueline Cronje
-
Patent number: 9662299Abstract: The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles. The present invention further relates to methods of making the yeast cell wall particles loaded with nanoparticles. The present invention also relates to methods of using the yeast cell wall particles loaded with nanoparticles for receptor-targeted delivery of the nanoparticles, e.g., drug containing nanoparticles.Type: GrantFiled: December 16, 2015Date of Patent: May 30, 2017Assignee: UNIVERSITY OF MASSACHUSETTSInventors: Gary R. Ostroff, Ernesto Soto
-
Patent number: 9662408Abstract: The present invention relates to a fiducial marker comprising barium sulfate (BaSO4), a solvent, and a polyethylene glycol-poly(aminourethaneurea) multi-block copolymer, as active ingredients. The fiducial marker of the present invention has an effect of significantly remedying disadvantages of image distortion and dose distortion, which are involved in the gold inner marker used in the conventional art. The fiducial marker of the present invention has very limited in vivo mobility, and thus the fiducial marker is maintained at the position at which it has been initially injected. Since the fiducial marker of the present invention is maintained in a sol or liquid state before in vivo injection, and transited into a gel or solid phase after in vivo injection, the injectability of the fiducial marker by an injector syringe is favorable, and the state of the fiducial marker can be controlled into a phase suitable to each site of the therapeutic target.Type: GrantFiled: October 21, 2015Date of Patent: May 30, 2017Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITYInventors: Young Yih Han, Hee Chul Park, Doo Sung Lee, Jae Myoung Noh, Sang Hee Ahn, Hye Young Kim, Moon Soo Gil
-
Patent number: 9662387Abstract: The present invention provides optical agents comprising optically functional cross linked supramolecular structures and assemblies useful for tandem optical imaging and therapy. Supramolecular structures and assemblies of the present invention include optically functional shell-cross linked micelles wherein optical functionality is achieved via incorporation of one or more linking groups that include one or more photoactive moieties. The present invention further includes imaging and therapeutic methods using one or more optical agents of the present invention including optically functional shell cross-linked micelles having an associated therapeutic agent.Type: GrantFiled: February 26, 2016Date of Patent: May 30, 2017Assignees: Mallinckrodt LLC, Washington University, The Texas A&M University SystemInventors: William L. Neumann, Richard B. Dorshow, John N. Freskos, Karen L. Wooley, Nam S. Lee, Yun Lin, Guorong Sun
-
Patent number: 9655980Abstract: A compound that includes a quaterrylene dye moiety as core, and a dendrimeric shell. For example, the compound may comprise at least four dendronized polyamides covalently attached to a quaterrylene dye. Also disclosed is a compound, or a pharmaceutically acceptable salt or ester thereof, comprising A(G)x, wherein: A comprises a quaterrylene dye; G comprises at least one functionalized dendrimeric structure; and x is 2 to 16. The compounds may be used for in methods for monitoring a therapeutic or diagnostic agent in a subject, or for treating a subject by administering the compound to the subject.Type: GrantFiled: July 31, 2013Date of Patent: May 23, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Mingfeng Bai, Pin Shao
-
Patent number: 9649175Abstract: A hydrogel plug is placed under stress during its curing stage, in one embodiment, by application of an externally applied force. The stress may also be induced during or after the dehydration process. The direction of the externally applied force increases the length, width, depth, or radial extent of the plug. The elastic limit of the plug is exceeded when the external force is applied so that the plug substantially retains its stressed size and shape when the externally applied force is removed. When the stretched or otherwise deformed dehydrated plug is hydrated, it substantially returns to the configuration it had prior to its dehydration and prior to the application of the externally applied force.Type: GrantFiled: May 19, 2016Date of Patent: May 16, 2017Assignee: DEVICOR MEDICAL PRODUCTS, INC.Inventors: Frederick A. Ahari, John S. Fisher
-
Patent number: 9642926Abstract: Compositions useful for target detection, imaging and treatment, as well as methods of production and use thereof, are disclosed herein.Type: GrantFiled: September 26, 2011Date of Patent: May 9, 2017Assignee: Siemens Medical Solutions USA, Inc.Inventors: Les Oppenheimer, Ismayil M. Guracar
-
Patent number: 9642815Abstract: In this work we have targeted two aspects of GQDs, Size and ROS to reduce their cytotoxicity. Small size can damage cell organelles and production of ROS (reactive oxygen species) can hamper cell machinery in multiple ways. We have shown that cytotoxicity can be significantly reduced by embedding GQDs inside the PEG matrix rather than creating a thin shell around each GQD. Thin PEG shell around GQD can control ROS production but cannot circumvent the toxicity due to small size. Thus it was essential to solve both the issues. We have used a simple electrochemical method (12 h at room temperature) for synthesizing GQDs and embedded them in PEG matrix via a simple one step hydrothermal reaction (24 h at 160° C.) involving only GQDs, PEG, and deionized water. The P-GQDs formed after hydrothermal reaction show nanoparticles of diameter of ˜80-100 nm containing GQDs entrapped in PEG matrix. MTT assay showed significant 60% cells viability at a very high concentration of 5.Type: GrantFiled: November 3, 2014Date of Patent: May 9, 2017Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCHInventors: Neetu Singh, Anil Chandra
-
Patent number: 9636189Abstract: A hydrogel plug is placed under stress during its curing stage, in one embodiment, by application of an externally applied force. The stress may also be induced during or after the dehydration process. The direction of the externally applied force increases the length, width, depth, or radial extent of the plug. The elastic limit of the plug is exceeded when the external force is applied so that the plug substantially retains its stressed size and shape when the externally applied force is removed. When the stretched or otherwise deformed dehydrated plug is hydrated, it substantially returns to the configuration it had prior to its dehydration and prior to the application of the externally applied force.Type: GrantFiled: June 6, 2013Date of Patent: May 2, 2017Assignee: DEVICOR MEDICAL PRODUCTS, INC.Inventors: Frederick A. Ahari, John S. Fisher
-
Patent number: 9637443Abstract: A method for forming a graphene quantum dot product includes adding an organic starting material to a vessel and heating the organic starting material to a temperature within 20° C. of the organic starting material's boiling temperature for a time no longer than ten minutes to form graphene quantum dots. A method for sensing a graphene quantum dot includes forming a graphene quantum dot, exciting the graphene quantum dot with light having a first wavelength, measuring light emitted by the excited graphene quantum dot at a second wavelength different from the first wavelength. A graphene quantum dot includes carbon atoms and nitrogen atoms where the nitrogen atoms are present within the graphene quantum dot at a level between 6.0% and 11.0% of a level of carbon atoms present in the graphene quantum dot.Type: GrantFiled: April 25, 2014Date of Patent: May 2, 2017Assignee: University of North DakotaInventors: Julia Xiaojun Zhao, Xu Wu
-
Patent number: 9629932Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.Type: GrantFiled: October 8, 2015Date of Patent: April 25, 2017Assignee: SANOCHEMIA PHARMAZEUTIKA AGInventors: Stefan Welzig, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
-
Patent number: 9623126Abstract: A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.Type: GrantFiled: January 9, 2015Date of Patent: April 18, 2017Assignee: The General Hospital CorporationInventors: Ralph Weissleder, Hakho Lee, Tae-Jong Yoon
-
Patent number: 9624255Abstract: Tumors can be selectively targeted via compounds provided herein according to the formula, or a pharmaceutically acceptable salt thereof, wherein RA and RB are as defined herein. Tumors can be imaged or targeted for therapeutic treatment using compounds described herein where at least one RA or at least one RB group comprises a imaging agent, a therapeutic agent, or a member of a specific binding pair which can be associated with a secondary imaging agent, such as a microbubble for ultrasonic imaging.Type: GrantFiled: May 5, 2010Date of Patent: April 18, 2017Assignee: Arizona Board of RegentsInventors: Sidney Hecht, Ryan Schmaltz, Krystal Tsosie